Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M163Revenue (TTM) $M89.3Net Margin (%)507Altman Z-Score-2.6
Enterprise Value $M106EPS (TTM) $34.1Operating Margin %-93.1Piotroski F-Score5
P/E(ttm)0.3Beneish M-Score12.1Pre-tax Margin (%)-139.0Higher ROA y-yY
Price/Book1.510-y EBITDA Growth Rate %--Quick Ratio3.3Cash flow > EarningsN
Price/Sales2.65-y EBITDA Growth Rate %-27.6Current Ratio3.3Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)333Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M13.3ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with MACK

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

MACK is held by these investors:



MACK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Nielsen Ulrik B.Director 2017-09-15Sell7,896$14.23-14.05view
Nielsen Ulrik B.Director 2017-09-13Sell21,556$14.4-15.07view
Drummond Daryl CHead of Research 2017-05-12Sell410$37.2-67.12view
Schoeberl Birgit M.Head of Discovery 2016-07-25Sell5,000$55-77.76view
PORTER MICHAEL EDirector 2016-03-17Buy500$72-83.01view
PORTER MICHAEL EDirector 2016-03-15Buy500$76.5-84.01view
PORTER MICHAEL EDirector 2016-03-08Buy1,000$70.9-82.75view
PORTER MICHAEL EDirector 2016-03-03Buy1,500$63.9-80.86view
PORTER MICHAEL EDirector 2016-03-01Buy2,000$61.1-79.98view
Lee Vivian SDirector 2016-02-29Buy3,500$55-77.76view

Quarterly/Annual Reports about MACK:

    News about MACK:

    Articles On GuruFocus.com
    Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed™ Im Nov 14 2017 
    Merrimack Reports Third Quarter 2017 Financial Results Nov 08 2017 
    Merrimack Announces Timing of Third Quarter 2017 Investor Conference Call Nov 01 2017 
    Merrimack Receives Orphan Drug Designation for MM-121 for the Treatment of Heregulin Positive Non-sm Oct 30 2017 
    Merrimack Commences Tender Offer for Any and All of its Outstanding 4.50% Convertible Senior Notes D Oct 13 2017 
    Merrimack Announces Settlement of Convertible Note Litigation Oct 10 2017 
    Merrimack Announces Date of One-for-Ten Reverse Stock Split Aug 31 2017 
    Merrimack Augments Executive Team with Appointment of Jean Franchi as Chief Financial Officer Aug 14 2017 
    Merrimack Reports Second Quarter 2017 Financial Results Aug 09 2017 
    Merrimack Announces Timing of Second Quarter 2017 Investor Conference Call Aug 02 2017 
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat

    {{numOfNotice}}
    FEEDBACK